Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405660 · ClinicalTrials.gov registry record · Phase 2
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
A Phase 2 study of Chronic Inducible Urticaria, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
- 20
- Study locations
NCT05405660 is a Phase 2 study of Chronic Inducible Urticaria that has completed, run by Celldex Therapeutics. The registered enrollment target is 196 participants, roughly in line with the 185-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT05405660, a Phase 2 study of Chronic Inducible Urticaria, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.
Conditions Studied
Interventions
- DRUG Matching Placebo
- BIOLOGICAL barzolvolimab
Study Locations (20)
Other
- Outpatient Clinic for Individual Practice for Specialized Outpatient - Razgrad
- Medical Center Iskar- EOOD Office of Clinical Allergology - Sofia
- "Medical Center Ekselsior" OOD - Sofia
- "University Multiprofile Hospital for Active Treatment 'Aleksandrovska" EAD, Clinic of Clinical Allergology - Sofia
Alabama
- Clinical Research Center of Alabama - Birmingham
- Allervie Clinical Research - Montgomery
California
- Kern Research, Inc - Bakersfield
- Allergy & Asthma Consultants - Redwood City
Arizona
- One of a Kind Clinical Research Center, LLC - Paradise Valley
Arkansas
- Little Rock Allergy & Asthma CRC - Little Rock
Colorado
- IMMUNOe Research Centers - Centennial
Florida
- Sarasota Clinical Research - Sarasota
Idaho
- Treasure Valley Medical Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2025-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05405660
The ClinicalTrials.gov registry entry for NCT05405660 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 185-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inducible Urticaria appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05405660 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05405660 about?
NCT05405660 is a clinical study titled "A Study of CDX-0159 in Patients With Chronic Inducible Urticaria". The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.
What is the current status of trial NCT05405660?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2022-06-28. Estimated completion is 2025-09-12.
What conditions does trial NCT05405660 study?
This clinical trial studies the following conditions: Chronic Inducible Urticaria.
What interventions are being tested in trial NCT05405660?
The interventions under investigation include: Matching Placebo (DRUG), barzolvolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05405660?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05405660 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inducible Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
RECRUITING · Phase 3
-
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.